Structure-based Virtual Screening for Hinokitiol (ß-thujaplicin) Copper Chelatedocked against Profusion structure of 2019-nCoV Spike Glycoprotein with a Single Receptor-binding Domain

SBDD- Structure Based Drug Discovery is a vital tool for 'In silico' (pseudo-Latin term for in-silicon that refers to huge use of silicon in processor chips as an expression to mean computer simulation) study in medicine. It is a fast and cost-efficient drug discovery and optimization technique and has been proven to be more efficient than conservational techniques since it aims to recognize the molecular basis of a sickness and utilizes the understanding of 3-dimensional structure of the genetic target to design an efficient drug. In this paper we will focus on the virtual screening of Hinokitiol (P-Thujaplicin Copper Chelate docked docked against the profusion structure of 2019-nCoV Spike Glycoprotein with a Single Receptor-Binding domain to study and examine the action of Hinokitiol Copper Chelate as an anti-viral drug against the Spike Glycoprotein of nCoV-2019. [ABSTRACT FROM AUTHOR]

Copyright of International Journal of Pharmaceutical Research (09752366) is the property of Association of Indian Pharmacist and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)